The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Issue 3 (11th February 2022)

• Record Type: Journal Article
• Authors: Cunningham, Richard; Hansen, Carsten Gram
• Is Part Of: Clinical science. Volume 136:Issue 3(2022)
• Page Start: 197
• Page End: 222
• Publication Date: 2022-02-11
• Subjects: AlphaFold -- Cancer -- Hippo pathway -- Immuno-oncology -- Mesothelioma -- Sarcoma; Medicine -- Periodicals; Biochemistry -- Periodicals; 616
• DOI: 10.1042/CS20201474
• Languages: English
• ISSNs: 0143-5221

Abstract

Abstract: Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.